-- Merck KGaA's Serono Unit Says Primary Endpoint of Erbitux Study Wasn' Met
-- B y   B i l l   K o e n i g
-- 2010-10-11T13:53:41Z
-- http://www.bloomberg.com/news/2010-10-11/merck-kgaa-s-serono-unit-says-primary-endpoint-of-erbitux-study-wasn-met.html
Merck Serono, a division of Merck
KGaA, said a Phase 2 study of Erbitux didnâ€™t meet primary
endpoint of response rate.  To contact the editor responsible for this story:
Bill Koenig at 
 wkoenig@bloomberg.net  